Role of Rituximab in the Treatment of Pemphigus Vulgaris: Patient Selection and Acceptability

Anti-CD20 monoclonal antibody rituximab is an approved adjuvant treatment, in combination with oral corticosteroids, for patients with pemphigus vulgaris, a severe and potentially life-threatening autoimmune blistering skin disorder. Updated approaches to the management of pemphigus vulgaris support...

Descripción completa

Detalles Bibliográficos
Autores principales: Ciolfi, Christian, Sernicola, Alvise, Alaibac, Mauro
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2022
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9651071/
https://www.ncbi.nlm.nih.gov/pubmed/36387051
http://dx.doi.org/10.2147/PPA.S350756

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9651071/
https://www.ncbi.nlm.nih.gov/pubmed/36387051
http://dx.doi.org/10.2147/PPA.S350756

Ejemplares similares